| 27.16 -1.1 (-3.89%) | 05-29 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 35.51 | 1-year : | 41.48 |
| Resists | First : | 30.4 | Second : | 35.51 |
| Pivot price | 27.97 |
|||
| Supports | First : | 25.45 | Second : | 22.39 |
| MAs | MA(5) : | 28.56 |
MA(20) : | 27.78  |
| MA(100) : | 21.23 |
MA(250) : | 28.17 |
|
| MACD | MACD : | 1.3 |
Signal : | 1.6 |
| %K %D | K(14,3) : | 62.7 |
D(3) : | 72.8 |
| RSI | RSI(14): 53.2 |
|||
| 52-week | High : | 45.29 | Low : | 16.23 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ LEGN ] has closed above bottom band by 29.2%. Bollinger Bands are 26.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 28.32 - 28.49 | 28.49 - 28.62 |
| Low: | 26.13 - 26.35 | 26.35 - 26.51 |
| Close: | 26.87 - 27.2 | 27.2 - 27.44 |
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
Fri, 29 May 2026
Legend Biotech (LEGN) Nears Adjusted Profitability This Year Amid Continued CARVYKTI Growth - Yahoo Finance
Wed, 27 May 2026
H.C. Wainwright reiterates Legend Biotech stock rating at buy - Investing.com
Mon, 25 May 2026
Legend Biotech Corporation (LEGN) Stock Analysis: Unveiling an 88.61% Potential Upside in Biotechnology - DirectorsTalk Interviews
Sun, 24 May 2026
Legend Biotech (LEGN) Is Up 6.6% After Strong Q1 And New CAR-T Data Release - Has The Bull Case Changed? - simplywall.st
Thu, 21 May 2026
ASCO 2026 to spotlight Legend Biotech (NASDAQ: LEGN) CAR-T and safety data - Stock Titan
Fri, 15 May 2026
Legend Biotech Corporation 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:LEGN) 2026-05-15 - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 186 (M) |
| Shares Float | 164 (M) |
| Held by Insiders | 1.3 (%) |
| Held by Institutions | 54.2 (%) |
| Shares Short | 17,000 (K) |
| Shares Short P.Month | 18,700 (K) |
| EPS | -1.38 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.42 |
| Profit Margin | -22 % |
| Operating Margin | -16.4 % |
| Return on Assets (ttm) | -5.3 % |
| Return on Equity (ttm) | -25.2 % |
| Qtrly Rev. Growth | 56.4 % |
| Gross Profit (p.s.) | 1.22 |
| Sales Per Share | 6.13 |
| EBITDA (p.s.) | -0.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -82 (M) |
| Levered Free Cash Flow | -65 (M) |
| PE Ratio | -19.69 |
| PEG Ratio | 0 |
| Price to Book value | 5.01 |
| Price to Sales | 4.42 |
| Price to Cash Flow | -61.75 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|